- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Bhuvana Sagar, MD, Discusses Maintaining Cost Efficiency While Using Biosimilars
Bhuvana Sagar, MD, the national medical executive at Cigna Health Care, discusses the importance of maintaining cost efficiency when juggling multiple biosimilars for 1 originator in the practice setting.
Bhuvana Sagar, MD, the national medical executive at Cigna Health Care, discusses how Cigna has balanced using multiple biosimilars for 1 originator while also maintaining cost efficiency.
As more biosimilars enter the market, competition for market share overall helps to decrease the total cost of care; however, too many choices for a reference drug can create cost inefficiencies.
Sagar explained that in order to manage this, Cigna met with its large providers, including community oncologists and others, to gain feedback on current practice issues.
Knowing which drugs are on the market and which ones are gaining the most market share helps to lower the unit cost for prescriptions and ensures cost-efficiency for both patients and employers. Sagar said that working with providers is how Cigna makes sure that providers can accommodate their policies as easily as possible.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
